Astellas Institute for Regenerative Medicine, a clinical stage biotechnology company, develops and commercializes regenerative ophthalmology therapeutics in the United States. The company is conducting various clinical trials for treating Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration, as well as pre-clinical trials for the treatment of other ocular disorders; and has pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory, and wound healing-related disorders. Its intellectual property portfolio includes pluripotent stem cell platforms, such as human embryonic stem cell and induced pluripotent stem cell platforms. The company’s intellectual property portfolio also comprises cell therapy research programs, such as ophthalmology programs, which include macular degeneration, photoreceptor progenitor, retinal ganglion cell progenitor, and corneal endothelial programs; and other programs, such as mesenchymal stem cell, neuroprotective biological, and platelet programs. As of February 11, 2015, it had 58 issued patents and 180 pending patent applications for the development of intellectual property portfolio. Astellas Institute for Regenerative Medicine was formerly known as Ocata Therapeutics, Inc. and changed its name to Astellas Institute for Regenerative Medicine in May 2016 as a result of acquisition by Astellas US Holding, Inc. The company was founded in 1994 and is headquartered in Marlborough, Massachusetts. As of February 9, 2016, Astellas Institute for Regenerative Medicine operates as a subsidiary of Astellas US Holding, Inc.